Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

878 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy.
Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi K, Homma S, Kishi K; Investigators Group for Lung Cancer and IIP. Miyamoto A, et al. Sci Rep. 2024 May 3;14(1):10162. doi: 10.1038/s41598-024-60833-w. Sci Rep. 2024. PMID: 38702426 Free PMC article.
Amino acid catabolite markers for early prognostication of pneumonia in patients with COVID-19.
Maeda R, Seki N, Uwamino Y, Wakui M, Nakagama Y, Kido Y, Sasai M, Taira S, Toriu N, Yamamoto M, Matsuura Y, Uchiyama J, Yamaguchi G, Hirakawa M, Kim YG, Mishima M, Yanagita M, Suematsu M, Sugiura Y. Maeda R, et al. Among authors: mishima m. Nat Commun. 2023 Dec 20;14(1):8469. doi: 10.1038/s41467-023-44266-z. Nat Commun. 2023. PMID: 38123556 Free PMC article.
A monomeric StayGold fluorescent protein.
Ivorra-Molla E, Akhuli D, McAndrew MBL, Scott W, Kumar L, Palani S, Mishima M, Crow A, Balasubramanian MK. Ivorra-Molla E, et al. Among authors: mishima m. Nat Biotechnol. 2023 Dec 11. doi: 10.1038/s41587-023-02018-w. Online ahead of print. Nat Biotechnol. 2023. PMID: 38081970
Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion.
Arata Y, Motoyama S, Yano M, Ikuno T, Ito S, Matsushita T, Takeiri A, Nishito Y, Yabuki N, Mizuno H, Sampei Z, Mishima M, Honda M, Kiyokawa J, Suzuki H, Chiba S, Tabo M, Kubo C. Arata Y, et al. Among authors: mishima m. MAbs. 2023 Jan-Dec;15(1):2253570. doi: 10.1080/19420862.2023.2253570. MAbs. 2023. PMID: 37682072 Free PMC article.
878 results